Results 181 to 190 of about 190,830 (306)
Microbes and medicines: interrelationships between pharmaceuticals and the gut microbiome. [PDF]
Al-Btoosh S, Donnelly RF, Kelly SA.
europepmc +1 more source
Halorotetin B, a novel small‐molecule terpenoid identified from an edible marine ascidian, exhibits strong anti‐tumor activity both in vitro and in vivo through direct targeting UBE2C to induce tumor cell cycle arrest and then lead tumor cell senescence. As a newly discovered UBE2C inhibitor, Halorotetin B can serve as a novel potential cell senescence
Shanhao Han +6 more
wiley +1 more source
Phage therapy and the microbiome in hematologic malignancies: opportunities, mechanisms, and early evidence. [PDF]
Zhang J, Liu J, Bayani A.
europepmc +1 more source
An iron‐based nanozyme selectively eliminates intratumoral P. anaerobius while catalytically generating ROS to induce ferroptosis, synergistically suppressing colorectal cancer growth and activating anti‐tumor immunity through immunogenic cell death. ABSTRACT The intratumoral microbiota is a critical determinant of therapeutic outcomes in colorectal ...
Yinghao Cao +11 more
wiley +1 more source
Biofilms: from the cradle of life to life support. [PDF]
Baxter KJ +22 more
europepmc +1 more source
DR5 knockout exhibits a thinner colonic mucus layer, leading to mild dysbiosis, increased susceptibility to Citrobacter rodentium invasion, and exacerbated epithelial injury. Mechanistically, DR5 binds transcription factor TBP, which regulates the expression of gene Best2 via its promoter.
Ying Wang +9 more
wiley +1 more source
ARKbase: Antimicrobial Resistance Knowledgebase1.0. [PDF]
Gambhir S +14 more
europepmc +1 more source
An AMP (P 3‐3R‐8I) based on natural peptides, which can target bacterial cell membranes, was precisely constructed via amino acid mutation. P 3‐3R‐8I exhibits antibacterial capability which could be attributed to the ability of P 3‐3R‐8I to quickly penetrate bacterial cell membranes and then to bind to bacterial DNA.
Jiaqi Huang +11 more
wiley +1 more source
Cell-to-Cell and Patient-to-Patient Variability in Antimicrobial Resistance. [PDF]
Huang X, Huang J, Zhong CC, Wong MCS.
europepmc +1 more source

